Clinical trials: Patients with Advanced Solid Tumors
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Tumors
Study With Atu027 in Patients With Advanced Solid Cancer
This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as…
- Trial name
- NCT00938574
- Testing
- Atu027
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Silence Therapeutics GmbH
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Trial name
- NCT04449874
- Testing
- GDC-6036, Atezolizumab, Cetuximab
- Where
- 63 sites in United States, Australia and 15 more
- Volunteers
- 498 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.
- Trial name
- NCT01286974
- Testing
- [14C]linifanib, ABT-869, linifanib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Abbott
Advanced Solid Tumors
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
The study is being conducted to evaluate safety, tolerability and preliminary efficacy of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) for advanced solid…
- Trial name
- NCT05214976
- Testing
- Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.
- Trial name
- NCT02259010
- Testing
- Alisertib, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Solid Tumors
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
The goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant…
- Trial name
- NCT07272590
- Testing
- QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion
- Volunteers
- 290 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and…
- Trial name
- NCT06953323
- Testing
- WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin
- Where
- 10 sites in China
- Volunteers
- 86 people
- Sponsor
- Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Advanced Solid Tumor
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06426680
- Testing
- ILB-3101
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Innolake Biopharm
Advanced Solid Tumors
A Study of Talazoparib in Patients With Advanced Solid Tumors
This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.
- Trial name
- NCT03070548
- Testing
- Talazoparib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Pfizer
Neoplasms
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.
- Trial name
- NCT02211859
- Testing
- BI 2536
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single…
- Trial name
- NCT04735978
- Testing
- RP3, Nivolumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 123 people
- Sponsor
- Replimune, Inc.
Neoplasms
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated…
- Trial name
- NCT01915576
- Testing
- BAY1125976
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 79 people
- Sponsor
- Bayer
Advanced Solid Tumors
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial, which aims to observe and evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of HRS2398…
- Trial name
- NCT06439589
- Testing
- HRS2398, Adebrelimab
- Where
- 2 sites in China
- Volunteers
- 88 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in…
- Trial name
- NCT05886868
- Testing
- BL0020
- Where
- 4 sites in Australia, China
- Volunteers
- 66 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.